急性髓细胞白血病Bcl-2蛋白表达及其临床意义  

Expression of Bcl-2 and P170 in acute myelocytic leukemia and clinical significance

作　　者：裘哲君[1] 王健民[1] 闻宏升[1] 夏炎春[2] 

机构地区：[1]第二军医大学附属长海医院血液科,上海200433 [2]解放军第113医院血液科,浙江宁波315040

出　　处：《中国误诊学杂志》2008年第16期3784-3786,共3页Chinese Journal of Misdiagnostics

摘　　要：目的:检测急性髓细胞白血病(AML)Bcl-2蛋白,并评价其与AML患者临床特征及多药耐药基因MDR1表达产物P170的关系。方法:免疫细胞化学ABC法检测白血病细胞中Bcl-2蛋白及P170表达。结果:AML中存在Bcl-2高水平表达,但复发的AML与初发AMLBcl-2表达无显著差异(P>0.05)。初发AML中,Bcl-2阳性组患者完全缓解(CR)率显著低于Bcl-2阴性组(P<0.01)。Bcl-2的阳性与阴性组中P170表达无显著差异(P>0.05)。Bcl-2和P170间无相关表达(rs=0.171,P>0.05),但Bcl-2/P170双阳性组化疗CR率显著低于双阴性组(P<0.01)或P170/Bcl-2单阳性组(P<0.05)。结论:初发AML中Bcl-2蛋白高水平表达与化疗耐药有关;Bcl-2与P170联合表达患者化疗反应更差。Objective：To detect the expression of Bcl-2 in acute myelocytic leukemia（AML）,and evaluate the relationship between Bcl-2 and clinic characteristics of AML,and P170 product of multi-drug resistance genel （MDR1）. Method：Immunocytochemical ABC assay was adopted to detect Bcl-2 and P170 protein in the cells. Results：The higher expression of Bcl-2 was found in AML（P〈0.05）. But there was no significant difference of Bcl-2 expression between initial AML and relapsed AML（P〉0.05）. The higher expression of Bcl-2 in initial AML was closely related to the lower complete remission （CR） rate （P〈0.05）. The Bcl-2 expression was not correlated with the P170 expression in AML （r1= 0. 171 ,P〉0.05）. But the CR rate in Bcl-2 P170 both positive group was significantly lower than Bcl-2 or P170 positive group （P〈0. 05） or both negative group （P〈0. 01 ）. Conclusion：Bcl-2 and P170 can predict chemoresistance. The coexpression and P170 can predict chemoresistance more precisely.

关 键 词：白血病 粒细胞 急性/代谢 原癌基因蛋白质c-bcl-2/代谢 人类 

分 类 号：R733.712.053[医药卫生—肿瘤]